Recently, Johnson & Johnson announced it will lower the prices of certain prescription drugs in the U.S. market in exchange for tariff reductions on imports. This move is seen as a strategic response by the pharmaceutical giant to increasing pressure from U.S. government policies aimed at curbing high drug prices and adjusting trade regulations. Under the agreement, Johnson & Johnson has committed to reducing the list prices of several widely used medications by 10% to 30% over the coming years, covering key therapeutic areas such as immunology and oncology. In return, the U.S. government will grant tariff exemptions or preferential rates on certain active pharmaceutical ingredients and finished drugs imported from its overseas facilities.This initiative not only addresses public concerns over soaring drug costs but may also set a precedent for other pharmaceutical companies. In recent years, the U.S. government has intensified efforts to reduce prescription drug expenses, including empowering Medicare to negotiate drug prices under the Inflation Reduction Act. Johnson & Johnson’s proactive pricing adjustment reflects its alignment with evolving policy trends and aims to safeguard its market reputation and long-term commercial interests. Analysts note that while the price cuts are modest and primarily affect list prices rather than actual out-of-pocket costs, the move signals a potential shift toward broader industry-wide pricing reforms.
近日，强生公司（Johnson & Johnson）宣布将降低其在美国市场部分处方药的价格，以换取政府在进口关税方面的减免。这一举措被视为制药企业应对美国政府加强药品价格监管和贸易政策压力的策略性回应。根据协议，强生承诺在未来几年内将其多种常用药品的标价下调10%至30%，涵盖如免疫疾病、癌症治疗等关键领域药物。作为交换，美国政府同意对其从海外工厂进口的部分原料药和成品药给予关税豁免或优惠税率。此举不仅有助于缓解公众对高昂药价的不满，也可能为其他制药公司树立先例。近年来，美国政府持续推动降低处方药成本，包括通过《通胀削减法案》授权医保谈判药价。强生此次主动调整定价策略，既是对政策风向的顺应，也意在维护其市场声誉与长期商业利益。分析人士指出，尽管降价幅度有限且主要针对标价而非实际支付价格，但这一行动释放出行业可能迎来更广泛价格改革的信号。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11880.html